This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implement...ing TB care and prevention and R&D into new tools. This Global Plan has already informed the Global Fund Investment Case and the 2022 G20 deliberations on TB. It will serve as a key document for inspiring and aligning global advocacy efforts, such as for the upcoming UNHLM on TB in 2023.
more
On the road to ending TB
Highlights from the 30 highest TB burden countries
Copenhagen, Denmark, 24–25 August 2017
NSP Review
Engaging with South Africa’s National Strategic Plan for HIV, STIs and TB Edition 7 July – August 2013
A publication of the Treatment Action Campaign and SECTION27
GeneXpert: An imperfect rollout
TB in South African prisons: Where to now?
Decentralising DR-TB care: How far alon...g are we?
more
Collection of country-level good practices
Please download the latest report from the official website:
http://www.nacp.go.tz/site/publications/epidemiology-and-research-coordination
Facilitator's Guide. This guide is designed to assist facilitators in training community health workers (CHWs) and community volunteers (CVs) in integrating community-based TB services into their work. The training will help community workers who already provide numerous services to understand TB an...d contribute to prevention, care and support services in their communities
more
The report focuses on antibacterial resistance (ABR) in common bacterial pathogens. There is a major gap in knowledge about the magnitude of this problem. Antimicrobial resistance (AMR) threatens the effective revention and treatment of an ever-increasing range of infections caused by bacteria, para...sites, viruses and fungi. This WHO report, produced in collaboration with Member States and other partners, provides for the first time, as accurate a picture as is presently possible of the magnitude of AMR and the current state of surveillance globally. It examines the information on AMR, in particular antibacterial resistance (ABR), at country level worldwide.
more
The main aim of these guidelines is to enable the central units of national TB and HIV/AIDS programmes to support districts to plan, coordinate and implement collaborative TB/HIV activities. These guidelines reinforce current medical understanding, that highly active antiretroviral treatment (HAART)... has decreased TB incidence of people living with HIV/AIDS. They are comprehensive, giving an overview of the range of activities that could be undertaken in high burden TB/HIV countries or where a rising prevalence of HIV might fuel TB. Activities highlight the need for comprehensive care, prevention and support for adults living with HIV/AIDS. Comprehensive TB and HIV care and prevention rely on full implementation of the DOTS strategy as part of a wide ranging HIV/AIDS care and prevention programme as well as collaborative TB and HIV programme activities.
more
This document is an evidence-based policy for the implementation of sound tuberculosis (TB) infection control by all stake- holders. It recommends a combination of measures aimed at reducing the risk of TB transmission within populations. The emphasis is on early and rapid diagnosis, and proper mana...gement of TB patients.
more
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...LASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
more
This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.
Dans la plupart des pays, les services de lutte contre la tuberculose (TB) sont décentralisés jusqu’aux dispensaires
les plus périphériques et souvent au sein même des villages et des quartiers. Par contre, les services
de lutte contre le VIH/Sida sont généralement beaucoup plus centralis...és parce que la diffusion des
soins, notamment de la thérapie antirétrovirale (TARV), n’a commencé qu’assez récemment. De ce fait,
les patients qui ont besoin d’un traitement à la fois contre la tuberculose et le VIH/Sida peuvent être obligés
de se rendre dans deux établissements distincts et ainsi d’avoir à parcourir de longues distances pour
accéder aux soins. L’absence de services intégrés TB/VIH peut provoquer des retards dans le diagnostic
et le traitement, et même se traduire par un mauvais suivi des traitements, voire par des interruptions. Par
ailleurs, les patients ont à supporter la charge financière des frais de déplacement et des autres coûts indirects,
tels que de longs temps d’attente et une perte de revenu
more